Akash Tewari
Stock Analyst at Jefferies
(4.78)
# 579
Out of 5,116 analysts
513
Total ratings
57.6%
Success rate
12.9%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Reiterated: Buy | $138 | $85.86 | +60.73% | 41 | Nov 4, 2026 | |
| PFE Pfizer | Reiterated: Buy | $36 | $29.88 | +20.48% | 49 | Nov 3, 2026 | |
| LLY Eli Lilly and Company | Rated: Buy | $1,440 → $1,610 | $1,364.73 | +17.97% | 48 | Oct 29, 2026 | |
| ZYME Zymeworks | Reiterated: Buy | $50 → $52 | $28.74 | +80.96% | 8 | Oct 23, 2026 | |
| ETRA Electra Therapeutics | Initiated Coverage: Buy | $32 | $7.35 | +335.37% | 1 | Oct 13, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Buy | $68 → $76 | $63.13 | +20.39% | 14 | Oct 12, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterated: Buy | $890 → $930 | $902.90 | +3.00% | 36 | Oct 1, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $200 → $220 | $159.76 | +37.71% | 30 | Sep 29, 2026 | |
| VRTX Vertex Pharmaceuticals | Reiterated: Buy | $633 → $640 | $542.50 | +17.97% | 5 | Sep 23, 2026 | |
| ALKS Alkermes | Reiterated: Buy | $78 → $83 | $44.54 | +86.35% | 30 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $98 → $126 | $96.59 | +30.45% | 6 | Sep 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $13.01 | +284.32% | 1 | Sep 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $104 → $105 | $56.12 | +87.10% | 39 | Aug 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $21.86 | +128.73% | 2 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 → $48 | $14.10 | +240.43% | 3 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $38.80 | +131.96% | 10 | Jul 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $180 | $167.57 | +7.42% | 2 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $2.95 | +374.58% | 1 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $350 | $460.28 | -23.96% | 2 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $980 → $1,008 | $894.77 | +12.65% | 42 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 → $46 | $68.71 | -33.05% | 19 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 → $35 | $12.94 | +170.48% | 2 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $18 → $20 | $10.08 | n/a | 8 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $80 | $55.55 | n/a | 19 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $398 → $502 | $400.10 | n/a | 16 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $138 | $146.94 | n/a | 34 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $52 → $10 | $6.55 | n/a | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $183 | $227.32 | n/a | 18 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 → $2.5 | $1.71 | n/a | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $17 | $17.00 | n/a | 7 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $17 | $1.57 | n/a | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $18.97 | n/a | 2 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.19 | n/a | 2 | Jan 29, 2020 |
BioNTech SE
Nov 4, 2026
Reiterated: Buy
Price Target: $138
Current: $85.86
Upside: +60.73%
Pfizer
Nov 3, 2026
Reiterated: Buy
Price Target: $36
Current: $29.88
Upside: +20.48%
Eli Lilly and Company
Oct 29, 2026
Rated: Buy
Price Target: $1,440 → $1,610
Current: $1,364.73
Upside: +17.97%
Zymeworks
Oct 23, 2026
Reiterated: Buy
Price Target: $50 → $52
Current: $28.74
Upside: +80.96%
Electra Therapeutics
Oct 13, 2026
Initiated Coverage: Buy
Price Target: $32
Current: $7.35
Upside: +335.37%
Bristol-Myers Squibb Company
Oct 12, 2026
Reiterated: Buy
Price Target: $68 → $76
Current: $63.13
Upside: +20.39%
Regeneron Pharmaceuticals
Oct 1, 2026
Reiterated: Buy
Price Target: $890 → $930
Current: $902.90
Upside: +3.00%
Neurocrine Biosciences
Sep 29, 2026
Reiterated: Buy
Price Target: $200 → $220
Current: $159.76
Upside: +37.71%
Vertex Pharmaceuticals
Sep 23, 2026
Reiterated: Buy
Price Target: $633 → $640
Current: $542.50
Upside: +17.97%
Alkermes
Sep 22, 2026
Reiterated: Buy
Price Target: $78 → $83
Current: $44.54
Upside: +86.35%
Sep 9, 2026
Reiterated: Buy
Price Target: $98 → $126
Current: $96.59
Upside: +30.45%
Sep 1, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $13.01
Upside: +284.32%
Aug 31, 2026
Reiterated: Buy
Price Target: $104 → $105
Current: $56.12
Upside: +87.10%
Aug 11, 2026
Reiterated: Buy
Price Target: $50
Current: $21.86
Upside: +128.73%
Aug 11, 2026
Reiterated: Buy
Price Target: $40 → $48
Current: $14.10
Upside: +240.43%
Jul 15, 2026
Reiterated: Buy
Price Target: $90
Current: $38.80
Upside: +131.96%
May 22, 2026
Reiterated: Buy
Price Target: $180
Current: $167.57
Upside: +7.42%
Apr 30, 2026
Reiterated: Buy
Price Target: $14
Current: $2.95
Upside: +374.58%
Mar 10, 2026
Initiated Coverage: Hold
Price Target: $350
Current: $460.28
Upside: -23.96%
Feb 19, 2026
Reiterated: Buy
Price Target: $980 → $1,008
Current: $894.77
Upside: +12.65%
Dec 11, 2025
Reiterated: Buy
Price Target: $50 → $46
Current: $68.71
Upside: -33.05%
Dec 5, 2025
Reiterated: Buy
Price Target: $26 → $35
Current: $12.94
Upside: +170.48%
Oct 1, 2025
Upgraded: Buy
Price Target: $18 → $20
Current: $10.08
Upside: n/a
Sep 3, 2025
Reiterated: Buy
Price Target: $70 → $80
Current: $55.55
Upside: n/a
Aug 12, 2025
Reiterated: Buy
Price Target: $398 → $502
Current: $400.10
Upside: n/a
Jun 18, 2025
Reiterated: Buy
Price Target: $138
Current: $146.94
Upside: n/a
May 2, 2025
Downgraded: Hold
Price Target: $52 → $10
Current: $6.55
Upside: n/a
Apr 1, 2025
Reiterated: Buy
Price Target: $183
Current: $227.32
Upside: n/a
Jan 29, 2025
Reiterated: Hold
Price Target: $6 → $2.5
Current: $1.71
Upside: n/a
Dec 11, 2024
Rated: Buy
Price Target: $16 → $17
Current: $17.00
Upside: n/a
Dec 12, 2022
Initiated Coverage: Buy
Price Target: $17
Current: $1.57
Upside: n/a
Feb 26, 2021
Downgraded: Hold
Price Target: n/a
Current: $18.97
Upside: n/a
Jan 29, 2020
Downgraded: Hold
Price Target: n/a
Current: $11.19
Upside: n/a